New oral anticoagulants targeting thrombin or factor Xa have the potential to significantly change the management of venous thromboembolic disease compared to traditional therapies.
Does not support practice change in VTE; leaves open need for randomized trials of new oral anticoagulants.
Summary Thrombin plays an essential role in haemostasis and thrombosis; therefore, anticoagulant strategies focus on direct or indirect inhibition of thrombin or factor Xa. Over the last 60 years, key players in antithrombotic treatment have been unfractionated heparin and vitamin K antagonists (VAKs), such as coumarin. New oral anticoagulants, with different mechanisms of action and administration, have the potential to promote dramatic changes in the management of patients with venous thromboembolic disease. This review provides an overview of the newer anticoagulants likely to be used in this indication.
No takes yet. Share an insight, caveat, or question.
A 2012 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: